Navigation Links
Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
Date:8/24/2010

Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back... -- BEIJING, Aug. 24 /PRNewswire-Asia/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals Click to view news release full screen  

Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives

 

BEIJING, Aug. 24 /PRNewswire-Asia/ -- Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.

"Our whole family is delighted with this outcome," his mother commented in a Cellonis interview. "He is now no different from any other child at his school. There is no sign of diabetes anymore. He previously coughed a lot in spring and winter, but after the therapy we haven't seen him coughing at all. We are very pleased."

The boy's doctor during the treatment, Dr. Shi, is similarly satisfied. "The efficacy of our patient's treatment surprised me a lot," she commented. "He hasn't taken insulin injections for eight months, and so does not need to worry about his blood glucose during PE.

"Also, diabetes can stunt a child's growth, with diabetic children being smaller and weaker than other children, but he has grown more than 10cm during this last half year. This is excellent news."

Preventing Dangerous Complications From Diabetes

Diabetes can be especially damaging to children, as it also affects them socially. They have to take care when playing, maintain a healthy diet, and take unpleasant insulin injections daily. Children with diabetes have a much greater risk of complications such as those affecting the kidneys and eyes.

Conventional treatments cannot prevent long-term complications and often have harmful side effects. The Cellonis stem cell therapy is suitable for all ages, with no side effects reported.

"Stem cell treatment is a new hope for diabetes sufferers," Dr. Shi continued. "It can replace dysfunctional pancreatic cells, getting to the root of the disease. Stem cell treatment, both for diabetes and for many other diseases, represents a new age for medicine."

Cellonis Biotechnologies focuses on R&D and the clinical application of personalized stem cell therapies and immunotherapies for patients with diseases including cancer, diabetes and central nervous system disorders.

Urs. J. Lienert COO-International Cellonis Phone: +86-150-1054-7487 Email: ipsc@cellonis.com Web: http://www.diabetescelltreatment.com http://www.cellonis.com
'/>"/>

SOURCE Cellonis Biotechnologies Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. UC Riverside researcher develops novel method to grow human embryonic stem cells
4. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
7. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
8. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
9. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
10. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
11. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... conditions have influenced the most recent performances of select ... (NASDAQ: RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... by Grand View Research, global Biotech market size is expected to ...
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CESĀ® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
Breaking Biology News(10 mins):